Snapshot from Jul 19, 2026 at 14:14 UTC. For live data and tracking: View Live
Events / Business / Abu Dhabi DoH, Novartis sign genomics MoU
Business strategic partnership

Abu Dhabi DoH, Novartis sign genomics MoU

Analysis based on 6 articles · First reported Jun 26, 2026 · Last updated Jun 28, 2026

Sentiment
60
Attention
4
Articles
6
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

This collaboration is expected to positively impact the pharmaceutical and biotechnology markets by fostering innovation in genomics and precision medicine. It could lead to the development of new therapies and improved patient outcomes, potentially increasing market opportunities for companies like Novartis involved in such research. The strengthening of the genomics ecosystem in Abu Dhabi also positions the region as a hub for healthcare innovation.

Pharmaceuticals Biotechnology Healthcare
Event Summary

The United Arab Emirates — Department of Health – Abu Dhabi and Novartis Middle East FZE have signed a Memorandum of Understanding to collaborate on genomics research, scientific capacity building, and advanced therapies. This partnership aims to leverage Abu Dhabi's extensive Emirati Genome Program, which has sequenced over 900,000 genomes, with Novartis' global scientific expertise. The goal is to translate genomic insights into improved health outcomes, advance precision medicine, and strengthen local scientific capabilities within the United Arab Emirates and globally. The agreement was signed during a United Arab Emirates — Department of Health – Abu Dhabi delegation visit to the Novartis Biomedical Research site in San Diego, coinciding with the BIO International Convention 2026.

Entities Involved
govactor
United Arab Emirates — Department of Health – Abu Dhabi
The United Arab Emirates — Department of Health – Abu Dhabi is the regulator of the healthcare sector in Abu Dhabi and is partnering with Novartis to advance genomics research and healthcare innovation, strengthening its position in precision medicine.
Importance 90.0 Sentiment 70.0
stock
Novartis
Novartis, an innovative medicines company, is collaborating with the United Arab Emirates — Department of Health – Abu Dhabi to expand its global scientific expertise in genomics research and advanced therapies, potentially leading to new treatment developments and market opportunities.
Importance 90.0 Sentiment 60.0
oth
Emirati Genome Program
The Emirati Genome Program, which has sequenced over 900,000 genomes, serves as a foundation for this partnership, providing crucial insights for advancing precision medicine and population-specific research.
Importance 60.0 Sentiment 70.0
cnt
United Arab Emirates
The United Arab Emirates, specifically Abu Dhabi, benefits from this collaboration by strengthening its genomics ecosystem and advancing precision medicine for its population.
Importance 50.0 Sentiment 60.0
per
Mohamed Ezz Eldin
Mohamed Ezz Eldin, Head of Novartis GCC Cluster, expressed pride in strengthening the collaboration, highlighting Novartis' commitment to healthcare innovation in the UAE.
Importance 40.0 Sentiment 50.0
per
Asma Al Mannaei
Dr. Asma Al Mannaei, Executive Director of the Health Life Sciences Sector at the United Arab Emirates — Department of Health – Abu Dhabi, emphasized the importance of this collaboration in advancing personalized healthcare and disease prevention.
Importance 40.0 Sentiment 50.0
Relationships
United Arab Emirates — Department of Health – Abu Dhabi related ↔ United Arab Emirates
United Arab Emirates — Department of Health – Abu Dhabi related ↔ Asma Al Mannaei
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.